Publications en collaboration avec des chercheurs de Seoul St. Mary's Hospital (8)

2021

  1. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

    Annals of Hematology, Vol. 100, Núm. 4, pp. 1065-1077

2020

  1. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518

  2. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087

  2. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Leukemia, Vol. 32, Núm. 8, pp. 1799-1803

2017

  1. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832

2016

  1. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study

    The Lancet, Vol. 387, Núm. 10020, pp. 770-778

2014

  1. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

    Blood, Vol. 123, Núm. 26, pp. 4136-4142